Left- vs Right-Sided Colon Cancers

Videos - Colorectal Cancer, Video
Eric Van Cutsem, MD, PhD
The WCGIC chairperson, professor Eric Van Cutsem, MD, PhD, heads the Division of Digestive Oncology at University Hospitals Leuven and KU Leuven, Leuven, Belgium. He describes the difference between left- and right-sided colon cancers in terms of prognosis and response to therapy.
Related Items
An Expert Perspective on the Current and Future of Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, Ali McBride, PharmD, MS, BCPS
Videos published on November 30, 2020 in Interview with the Innovators, Video
Immunotherapy in Combination with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, Ali McBride, PharmD, MS, BCPS
Videos published on November 13, 2020 in Interview with the Innovators, Video
Adverse Events and Improvements in Quality of Life Associated with First-Line Maintenance Therapy in Ovarian Cancer
Paula Anastasia, RN, MN, AOCN, Ali McBride, PharmD, MS, BCPS
Videos published on November 2, 2020 in Interview with the Innovators, Video
Management of Adverse Events Associated with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on October 11, 2020 in Interview with the Innovators, Video
Combination Therapy as Maintenance in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on October 6, 2020 in Interview with the Innovators, Video
Clinical Data on First-Line Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on September 15, 2020 in Interview with the Innovators, Video
Pembrolizumab Doubles Progression-Free Survival in Subset of Patients with Metastatic Colorectal Cancer
Charlie Dawson
TOP - September 2020 Vol 13, No 5 published on September 14, 2020 in Colorectal Cancer
Nivolumab plus Ipilimumab May Be a New First-Line Option for Patients with MSI-H or dMMR Metastatic Colorectal Cancer
William King
TOP - September 2020 Vol 13, No 5 published on September 14, 2020 in Colorectal Cancer
Choosing Among PARP Inhibitors as Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on September 8, 2020 in Interview with the Innovators, Video
Choosing Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on August 18, 2020 in Interview with the Innovators, Video
Last modified: April 27, 2020